Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation.

Nature clinical practice. Oncology - 1 Oct 2007

Pan Minggui, Santamaria Monica, Wollman David B

Abstract excerpt

BACKGROUND: A 73-year-old Asian man with a history of lipidemia, hypertension and myocardial infarction presented with dizziness, decreased appetite, weight loss, nonproductive cough and fatigue. His physical performance status was good, and physical examination was unremarkable except for lower-extremity pitting edema. INVESTIGATIONS: Physical examination, brain MRI, CT scans of the chest, abdomen and pelvis,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Brain Neoplasms
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Erlotinib Hydrochloride

Share to Lung Neoplasms

Share to Protein Kinase Inhibitors

Share to Quinazolines

Source

Identifiers

PMID: 17898810
DOI: 10.1038/ncponc0931

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation.PMID 17898810Read ↗

Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer metastatic to the brain.Semantic proximity Read ↗

Brain Metastases in NSCLC - are TKIs Changing the Treatment Strategy?Semantic proximity Read ↗

Carcinomatosis under control by osimertinib in EGFR and TP53 mutated lung adenocarcinoma.Semantic proximity Read ↗

Erlotinib for the treatment of brain metastases in non-small cell lung cancer.Semantic proximity Read ↗

Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation.Semantic proximity Read ↗

Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer.Semantic proximity Read ↗

Medical Treatment Options for Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Suffering from Brain Metastases and/or Leptomeningeal Disease.Semantic proximity Read ↗

The effectiveness of erlotinib against brain metastases in non-small cell lung cancer patients.Semantic proximity Read ↗

Brief Report: EGFR L833V/H835L Duplex-Mutated NSCLC With Leptomeningeal Carcinomatosis Responsive to Osimertinib.Semantic proximity Read ↗

Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases.Semantic proximity Read ↗

Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain metastases.Semantic proximity Read ↗

[Molecular-Targeted Agents as a Novel Therapeutic Tool for Brain Metastases].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.